Ocugen, Inc. (OCGN) Discusses OCU410 Phase 2 ArMaDa Trial Data and Clinical Update for Geographic Atrophy Transcript

Core Viewpoint - Ocugen is discussing data from the first half of patients who have completed one year since treatment in the OCU410 Phase II ArMaDa clinical trial for geographic atrophy [1] Group 1: Company Overview - The webcast features key executives including Dr. Shankar Musunuri (Chairman, CEO, and Co-Founder), Dr. Huma Qamar (Chief Medical Officer), and Dr. Arun Upadhyay (Chief Scientific Officer) [1] - Distinguished clinical trial investigators are also participating in the discussion, including Dr. Jay Chhablani, Dr. Arshad Khanani, and Dr. Lejla Vajzovic [1] Group 2: Clinical Trial Insights - The focus of the webcast is on the clinical trial data related to the OCU410 treatment for geographic atrophy, highlighting the significance of the one-year patient data [1]